Top View
- Downregulation of Mir-506-3P Facilitates EGFR-TKI Resistance Through Induction of Sonic Hedgehog Signaling in Non-Small-Cell Lung Cancer Cell Lines
- Systemic Medications Linked to an Increased Risk for Skin Malignancy
- Oncology Orals Solid Tumors
- Hedgehog Signaling, a Critical Pathway Governing the Development and Progression of Hepatocellular Carcinoma
- Pharmacology Update
- The Anti-Angiogenic Compound Axitinib Demonstrates Low Toxicity and Anti-Tumoral Effects Against Medulloblastoma
- Odomzo (Sonidegib)
- Efficacy and Safety of Sonic Hedgehog Pathway Inhibitors in Cancer
- 2018 Annual Report
- Developmental Therapeutics
- Sorafenib: Drug Information
- Family Medicine and Primary Care: Open Access
- Hedgehog Signaling Inhibators and Their Importance for Cancer Treatment
- GLI1 Activation Is a Key Mechanism of Erlotinib Resistance in Human Non‑Small Cell Lung Cancer
- Therapeutic Advances in Oncology
- Safety and Efficacy of Combined Radiotherapy, Immunotherapy And
- Exovesicular-Shh Confers Imatinib Resistance by Upregulating Bcl2
- Auxiliary Label List
- Oncology Comprehensive Drug List Krogerspecialtypharmacy.Com
- Study Protocol and Statistical Analysis Plan
- CCR-21-3-Highlights 491..491
- Quality of Life for Patients with Advanced Basal Cell Carcinoma Treated with Hedgehog Signaling Pathway Inhibitors Michael R
- SAFE HANDLING of HAZARDOUS DRUGS Updated 5/22/2020
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- Sonidegib (Odomzo)- Updated December 2019
- Supplementary Table 1. Summary of FDA-Approved Anticancer Cytotoxic Drugs at May 2019
- Oncology Medications Policy (1403)
- Imatinib: Drug Information
- Review of Newly Approved Oncologic Therapies: 2014–2015
- New Advances and Challenges of Targeting Cancer Stem Cells Nurmaa K
- Cutaneous Squamous Cell Carcinoma: from Biology to Therapy
- Oncology Agents Policy #: Rx.01.67
- Odomzo, INN-Sonidegib
- PRECISION MEDICINE at the INFLECTION POINT Session PM1, March 5, 2018 Damon Hostin, CEO, Precision Medicine Alliance, LLC
- Melamed Udel 0060D 1
- Management of Cutaneous and Extracutaneous Side Effects of Smoothened Inhibitor Therapy for Advanced Basal Cell Carcinoma Shalini V
- Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
- Scheduling Delegates' Interim Decisions and Invitation for Further
- Systemic Therapy Update
- An Open Access Database of Licensed Cancer Drugs Pan Pantziarka 1,2, §, Rica Capistrano 1, Arno De Potter 3, Liese Vandeborne 1, Gauthier Bouche 1
- Generic (Brand) Name Mechanism of Action Mechanism of Action
- Methyltransferase Nsp16/Nsp10 Complex
- Hedgehog Pathway Inhibitors: a New Therapeutic Class for the Treatment of Acute Myeloid Leukemia
- Clinically Relevant Concentrations of Anticancer Drugs: a Guide for Nonclinical Studies Dane R
- Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia
- Oncology Oral Medications Enrollment Form
- Emetogenic Potential of Antineoplastic Agents
- Translating Discoveries Into Cures for Children with Cancer
- Meeting Program and Floor Plan
- Safe Handling of Oral Antineoplastic Medications: Focus on Targeted Therapeutics in the Home Setting
- Hazardous Medication Precautions: Personal Protective Equipment (Ppe)
- Hedgehog Signaling Inhibition in the Treatment of Basal Cell Carcinoma
- Hedgehog Signaling Pathway Affects the Sensitivity of Hepatoma Cells To